Form 8-K - Current report:
SEC Accession No. 0001437749-25-022878
Filing Date
2025-07-17
Accepted
2025-07-17 08:25:13
Documents
17
Period of Report
2025-07-17
Items
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K mbrx20250716_8k.htm   iXBRL 8-K 25717
2 EXHIBIT 99.1 ex_839482.htm EX-99.1 14306
7 a01.jpg GRAPHIC 10221
8 i01.jpg GRAPHIC 7744
9 logobig.jpg GRAPHIC 19220
  Complete submission text file 0001437749-25-022878.txt   244379

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA mbrx-20250717.xsd EX-101.SCH 3579
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE mbrx-20250717_def.xml EX-101.DEF 11807
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE mbrx-20250717_lab.xml EX-101.LAB 15858
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mbrx-20250717_pre.xml EX-101.PRE 12022
19 EXTRACTED XBRL INSTANCE DOCUMENT mbrx20250716_8k_htm.xml XML 2946
Mailing Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007
Business Address 5300 MEMORIAL DRIVE SUITE 950 HOUSTON TX 77007 713-300-5160
Moleculin Biotech, Inc. (Filer) CIK: 0001659617 (see all company filings)

EIN.: 474671997 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37758 | Film No.: 251128916
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)